Changes of Cerebrospinal Fluid Tumor Marker Levels May Predict Response to Treatment and Survival of Carcinomatous Meningitis in Patients with Advanced Breast Cancer

2005 ◽  
Vol 22 (2) ◽  
pp. 123-128 ◽  
Author(s):  
Christos Kosmas ◽  
Nicolas B. Tsavaris ◽  
Georgia Soukouli ◽  
Panagiotis Gouveris ◽  
George Tsakonas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cerebrospinal Fluid ◽  
Advanced Breast Cancer ◽  
Tumor Marker ◽  
Advanced Breast ◽  
Response To Treatment ◽  
Carcinomatous Meningitis

Isolated Leptomeningeal Carcinomatosis (Carcinomatous Meningitis) after Taxane-Induced Major Remission in Patients with Advanced Breast Cancer

Oncology ◽  
2002 ◽  
Vol 63 (1) ◽  
pp. 6-15 ◽  
Author(s):  
Christos Kosmas ◽  
Nikolaos A. Malamos ◽  
Nikolas B. Tsavaris ◽  
Melina Stamataki ◽  
Achilleas Gregoriou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Leptomeningeal Carcinomatosis ◽  
Advanced Breast ◽  
Carcinomatous Meningitis

Association between molecular subtype of local advanced breast cancer with Ca 15-3 level

2021 ◽  
pp. 1-4
Author(s):  
Dony Ruswendro ◽  
Salman Ardi Syamsu ◽  
Rudy Thabry ◽  
Arifin Seweng ◽  
Andi Nilawati Usman
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Marker ◽  
Molecular Subtypes ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Tissue Growth ◽  
Advanced Breast ◽  
Luminal A ◽  
Luminal B

BACKGROUND: Neoplasm is an abnormal mass of tissue that grows excessively and not coordinated with normal tissue growth and continues to do so even though the stimulation that triggered the change has stopped. Breast cancer can be known by using tumor marker, which has been used is mucin-like glycoprotein Carcinoma Antigen (CA 15-3) which is a tumor marker that is specific to breast cancer. METHOD: This study is a cross-sectional study to determine the association between molecular subtypes of locally advanced breast cancer with CA 15-3 level at Abdul Wahab Sjahranie Samarinda Hospital. The population in this study were all breast cancer patients that were confirmed by histopathological examination. RESULTS: A total of 75 patients were included for this study, 29 patients (38.7%) known as Overexpression HER2, 18 patients (24.0%) were Luminal B with HER2 (+), 11 patients (14.7%) were Luminal B with HER2 (−), 11 patients (14.7%) were Basal-like/TNBC, and 6 patients (8,0%) were Luminal A. From the ANOVA test, the value of p = 0.045 (p < 0.05) means there was an association between Ca 15-3 level and molecular subtypes in patients with locally advanced breast cancer at the Abdul Wahab Sjahranie Hospital in Samarinda 2017. In this study Ca 15-3 levels were obtained on average for Luminal A 16.98 U/mL, Luminal B with HER2 (−) 42.41 U/mL, Luminal B with HER2 (+) 73.75 U/mL, Overexpression HER2 47.73 U/mL, and Basal Like /TNBC 63.50 U/mL. CONCLUSION: Statistically, it was found that there was an association between Ca 15-3 levels and molecular subtypes in patients with locally advanced breast cancer at the Abdul Wahab Sjahranie Hospital in Samarinda 2017.

1263 Advanced breast cancer (ABC) and CEA, MCA, CA 15.3: Correlation with response to treatment

1995 ◽  
Vol 31 ◽  
pp. S263-S264
Author(s):  
L. Moraglio ◽  
G. Pastorino ◽  
M.C. Martini ◽  
G.F. Addamo ◽  
G. Sogno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Response To Treatment ◽  
Ca 15.3

Plasma prolactin as a tumor marker in advanced breast cancer

1990 ◽  
Vol 26 (2) ◽  
pp. 177
Author(s):  
J.M. Bhatavdekar ◽  
N.G. Shah ◽  
D.D. Giri ◽  
N.H. Karelia ◽  
S.N. Trivedi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Marker ◽  
Advanced Breast ◽  
Plasma Prolactin

CA-549: A new tumor marker for patients with advanced breast cancer

1988 ◽  
Vol 2 (3) ◽  
pp. 168-173 ◽  
Author(s):  
Laurence M. Demers ◽  
Harold A. Harvey ◽  
Jerry D. Glenn ◽  
Pramod K. Gaur
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Tumor Marker ◽  
Advanced Breast
Sign in / Sign up

Export Citation Format

Share Document